Author
DEL GOBBO, LIANA - Stanford University School Of Medicine | |
IMAMURA, FUMIAKI - Cambridge University | |
ASLIBEKYAN, STELLA - University Of Alabama | |
MARKLUND, MATTI - Uppsala University | |
VIRTANEN, JYRKI - University Of Eastern Finland | |
WENNBERG, MARIA - University Of Umea | |
YAKOOB, MOHAMMAD - Stanford University School Of Medicine | |
CHIUVE, STEPHANIE - Brigham & Women'S Hospital | |
DELA GRUZ, LUICITO - Cancer Council Victoria | |
FRAZIER-WOOD, ALEXIS - Children'S Nutrition Research Center (CNRC) | |
FRETTS, AMANDA - University Of Washington | |
GUALLAR, ELISEO - Johns Hopkins School Of Public Health | |
MATSUMOTO, CHISA - Tokyo Medical And Dental University | |
PREM, KIESHA - National University Of Singapore | |
TANAKA, TOSH - National Institute On Aging (NIA, NIH) | |
WU, JASON - University Of Sydney | |
ZHOU, XIA - University Of Minnesota | |
HELMER, CATHERINE - Institut National De La Sante Et De La Recherche Medicale (INSERM) | |
INGELSSON, ERIK - Stanford University School Of Medicine | |
YUAN, JIAN - University Of Pittsburgh | |
BARBERGER-GATEAU, PASCALE - Institut National De La Sante Et De La Recherche Medicale (INSERM) | |
CAMPOS, HANNIA - Harvard School Of Public Health | |
CHAVES, PAULO - Florida International University | |
DJOUSSE, LUC - Brigham & Women'S Hospital | |
GILES, GRAHAM - Cancer Council Victoria | |
GOMEZ-ARACENA, JOSE - University Of Malaga | |
HODGE, ALLISON - Cancer Council Victoria | |
HU, FRANK - Brigham & Women'S Hospital | |
JANSON, JAN - University Of Umea | |
JOHANSSON, INGEGERD - University Of Umea | |
KHAW, KAY - University Of Cambridge | |
KOH, WOON - National University Of Singapore | |
LEMAITRE, ROZENN - University Of Washington | |
LIND, LARS - Uppsala University | |
LUBEN, ROBERT - University Of Cambridge | |
RIMM, ERIC - Brigham & Women'S Hospital | |
RISERUS, ULF - Uppsala University | |
SAMIERI, CECILIA - Institut National De La Sante Et De La Recherche Medicale (INSERM) | |
FRANKS, PAUL - Lund University | |
SISCOVICK, DAVID - New York Academy Of Medicine | |
STAMPFER, MEIR - Harvard School Of Public Health | |
STEFFEN, LYN - University Of Minnesota | |
STEFFEN, BRIAN - University Of Minnesota | |
TSAI, MICHAEL - University Of Minnesota | |
VAN DAM, ROB - National University Of Singapore | |
VOUTILAINEN, SARI - University Of Eastern Finland | |
WILLETT, WALTER - Harvard School Of Public Health | |
WOODWARD, MARK - Oxford University | |
MOZAFFARIAN, DARIUSH - Tufts University |
Submitted to: JAMA Internal Medicine
Publication Type: Peer Reviewed Journal Publication Acceptance Date: 5/3/2016 Publication Date: 8/1/2016 Citation: Del Gobbo, L.C., Imamura, F., Aslibekyan, S., Marklund, M., Virtanen, J.K., Wennberg, M., Yakoob, M.Y., Chiuve, S.E., Dela Gruz, L., Frazier-Wood, A.C., Fretts, A.M., Guallar, E., Matsumoto, C., Prem, K., Tanaka, T., Wu, J.H., Zhou, X., Helmer, C., Ingelsson, E., Yuan, J.M., Barberger-Gateau, P., Campos, H., Chaves, P.H., Djousse, L., Giles, G.G., Gomez-Aracena, J., Hodge, A.M., Hu, F.B., Janson, J.H., Johansson, I., Khaw, K.T., Koh, W.P., Lemaitre, R.N., Lind, L., Luben, R.N., Rimm, E.B., Riserus, U., Samieri, C., Franks, P.W., Siscovick, D.S., Stampfer, M., Steffen, L.M., Steffen, B.T., Tsai, M.Y., Van Dam, R.M., Voutilainen, S., Willett, W.C., Woodward, M., Mozaffarian, D. 2016. Omega-3 polyunsaturated fatty acid biomarkers and coronary heart disease: Pooling project of 19 cohort studies. JAMA Internal Medicine. 176(8):1155-1166. Interpretive Summary: Consumption of omega-3 polyunsaturated fatty acids (PUFAs) has been associated with a reduced risk of coronary heart disease (CHD), but the problem is that not all studies support this notion – many report no association making it unclear if dietary guidelines should emphasize omega-3 PUFA intake or not. Most prior longitudinal studies evaluated self-reported consumption rather than biomarkers, and since self-reported consumption can often be inaccurate, in this study we aimed to clarify the role of omega-3 PUFAs in health by evaluating the association of seafood-derived eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) and plant-derived a-linolenic acid (ALA) with incident CHD. We analyzed data from 19 studies across the globe and found that ALA, DPA, and DHA were associated with a lower risk of fatal CHD. DPA was associated with a lower risk of total CHD, other omega-3 PUFAs were not. These data suggest that biomarker concentrations of seafood and plant-derived omega-3 PUFAs are associated with a modestly lower incidence of fatal CHD, and so may be important to include in nutrition advice. Technical Abstract: The role of omega-3 polyunsaturated fatty acids for primary prevention of coronary heart disease (CHD) remains controversial. Most prior longitudinal studies evaluated self-reported consumption rather than biomarkers. This study sought to evaluate biomarkers of seafood-derived eicosapentaenoic acid (EPA; 20:5 omega-3), docosapentaenoic acid (DPA; 22:5 omega-3), and docosahexaenoic acid (DHA; 22:6 omega-3) and plant-derived a-linolenic acid (ALA; 18:3 omega-3) for incident CHD, using data from a global consortium of 19 studies identified by November 2014. Available prospective (cohort, nested case-control) or retrospective studies with circulating or tissue omega-3 biomarkers and ascertained CHD were selected. Each study conducted standardized, individual-level analysis using harmonized models, exposures, outcomes, and covariates. Findings were centrally pooled using random-effects meta-analysis. Heterogeneity was examined by age, sex, race, diabetes, statins, aspirin, omega-6 levels, and FADS desaturase genes. Incident total CHD, fatal CHD, and nonfatal myocardial infarction (MI) were measured. The 19 studies comprised 16 countries, 45,637 unique individuals, and 7973 total CHD, 2781 fatal CHD, and 7157 nonfatal MI events, with omega-3 measures in total plasma, phospholipids, cholesterol esters, and adipose tissue. Median age at baseline was 59 years (range, 18-97 years), and 28 660 (62.8%) were male. In continuous (per 1-SD increase) multivariable-adjusted analyses, the omega-3 biomarkers ALA, DPA, and DHA were associated with a lower risk of fatal CHD, with relative risks (RRs) of 0.91 (95% CI, 0.84-0.98) for ALA, 0.90 (95% CI, 0.85-0.96) for DPA, and 0.90 (95% CI, 0.84-0.96) for DHA. Although DPA was associated with a lower risk of total CHD (RR, 0.94; 95% CI, 0.90-0.99), ALA (RR, 1.00; 95% CI, 0.95-1.05), EPA (RR, 0.94; 95% CI, 0.87-1.02), and DHA (RR, 0.95; 95% CI, 0.91-1.00) were not. Significant associations with nonfatal MI were not evident. Associations appeared generally stronger in phospholipids and total plasma. Restricted cubic splines did not identify evidence of nonlinearity in dose responses. On the basis of available studies of free-living populations globally, biomarker concentrations of seafood and plant-derived omega-3 fatty acids are associated with a modestly lower incidence of fatal CHD. |